209 related articles for article (PubMed ID: 32154219)
1.
Pallante L; Rocca A; Klejborowska G; Huczynski A; Grasso G; Tuszynski JA; Deriu MA
Front Chem; 2020; 8():108. PubMed ID: 32154219
[TBL] [Abstract][Full Text] [Related]
2. Novel mutations involving βI-, βIIA-, or βIVB-tubulin isotypes with functional resemblance to βIII-tubulin in breast cancer.
Wang W; Zhang H; Wang X; Patterson J; Winter P; Graham K; Ghosh S; Lee JC; Katsetos CD; Mackey JR; Tuszynski JA; Wong GK; Ludueña RF
Protoplasma; 2017 May; 254(3):1163-1173. PubMed ID: 27943021
[TBL] [Abstract][Full Text] [Related]
3. Characterization of the colchicine binding site on avian tubulin isotype betaVI.
Sharma S; Poliks B; Chiauzzi C; Ravindra R; Blanden AR; Bane S
Biochemistry; 2010 Apr; 49(13):2932-42. PubMed ID: 20178367
[TBL] [Abstract][Full Text] [Related]
4. Synthesis, antiproliferative activity and molecular docking of thiocolchicine urethanes.
Majcher U; Urbaniak A; Maj E; Moshari M; Delgado M; Wietrzyk J; Bartl F; Chambers TC; Tuszynski JA; Huczyński A
Bioorg Chem; 2018 Dec; 81():553-566. PubMed ID: 30248507
[TBL] [Abstract][Full Text] [Related]
5. Effect of CH-35, a novel anti-tumor colchicine analogue, on breast cancer cells overexpressing the βIII isotype of tubulin.
Yeh LC; Banerjee A; Prasad V; Tuszynski JA; Weis AL; Bakos T; Yeh IT; Ludueña RF; Lee JC
Invest New Drugs; 2016 Feb; 34(1):129-37. PubMed ID: 26686345
[TBL] [Abstract][Full Text] [Related]
6. Exploring the interaction of Peloruside-A with drug resistant αβII and αβIII tubulin isotypes in human ovarian carcinoma using a molecular modeling approach.
Kumbhar BV; Bhandare VV
J Biomol Struct Dyn; 2021 Apr; 39(6):1990-2002. PubMed ID: 32241247
[TBL] [Abstract][Full Text] [Related]
7. Antiproliferative Activity and Molecular Docking of Novel Double-Modified Colchicine Derivatives.
Majcher U; Klejborowska G; Moshari M; Maj E; Wietrzyk J; Bartl F; Tuszynski JA; Huczyński A
Cells; 2018 Nov; 7(11):. PubMed ID: 30388878
[TBL] [Abstract][Full Text] [Related]
8. The roles of cys124 and ser239 in the functional properties of human betaIII tubulin.
Joe PA; Banerjee A; Ludueña RF
Cell Motil Cytoskeleton; 2008 Jun; 65(6):476-86. PubMed ID: 18435451
[TBL] [Abstract][Full Text] [Related]
9. Delineating the interaction of combretastatin A-4 with αβ tubulin isotypes present in drug resistant human lung carcinoma using a molecular modeling approach.
Kumbhar BV; Bhandare VV; Panda D; Kunwar A
J Biomol Struct Dyn; 2020 Feb; 38(2):426-438. PubMed ID: 30831055
[TBL] [Abstract][Full Text] [Related]
10. Exploring the Origin of Differential Binding Affinities of Human Tubulin Isotypes αβII, αβIII and αβIV for DAMA-Colchicine Using Homology Modelling, Molecular Docking and Molecular Dynamics Simulations.
Kumbhar BV; Borogaon A; Panda D; Kunwar A
PLoS One; 2016; 11(5):e0156048. PubMed ID: 27227832
[TBL] [Abstract][Full Text] [Related]
11. Interaction of microtubule depolymerizing agent indanocine with different human αβ tubulin isotypes.
Kumbhar BV; Panda D; Kunwar A
PLoS One; 2018; 13(3):e0194934. PubMed ID: 29584771
[TBL] [Abstract][Full Text] [Related]
12. Structure-based approaches for the design of benzimidazole-2-carbamate derivatives as tubulin polymerization inhibitors.
Aguayo-Ortiz R; Cano-González L; Castillo R; Hernández-Campos A; Dominguez L
Chem Biol Drug Des; 2017 Jul; 90(1):40-51. PubMed ID: 28004475
[TBL] [Abstract][Full Text] [Related]
13. Interaction of Colchicine-Site Ligands With the Blood Cell-Specific Isotype of β-Tubulin-Notable Affinity for Benzimidazoles.
Montecinos F; Loew M; Chio TI; Bane SL; Sackett DL
Front Cell Dev Biol; 2022; 10():884287. PubMed ID: 35712668
[TBL] [Abstract][Full Text] [Related]
14. Elucidation of the anticancer potential and tubulin isotype-specific interactions of β-sitosterol.
Pradhan M; Suri C; Choudhary S; Naik PK; Lopus M
J Biomol Struct Dyn; 2018 Jan; 36(1):195-208. PubMed ID: 27960611
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and Biological Evaluation of Novel Triple-Modified Colchicine Derivatives as Potent Tubulin-Targeting Anticancer Agents.
Majcher U; Klejborowska G; Kaik M; Maj E; Wietrzyk J; Moshari M; Preto J; Tuszynski JA; Huczyński A
Cells; 2018 Nov; 7(11):. PubMed ID: 30463236
[TBL] [Abstract][Full Text] [Related]
16. In Silico Exploration of Microtubule Agent Griseofulvin and Its Derivatives Interactions with Different Human β-Tubulin Isotypes.
Aris P; Mohamadzadeh M; Kruglikov A; Askari Rad M; Xia X
Molecules; 2023 Mar; 28(5):. PubMed ID: 36903629
[TBL] [Abstract][Full Text] [Related]
17. Computational study of interactions of anti-cancer drug eribulin with human tubulin isotypes.
Rai K; Kumbhar BV; Panda D; Kunwar A
Phys Chem Chem Phys; 2022 Jul; 24(27):16694-16700. PubMed ID: 35766982
[TBL] [Abstract][Full Text] [Related]
18. Identification and characterization of an intermediate taxol binding site within microtubule nanopores and a mechanism for tubulin isotype binding selectivity.
Freedman H; Huzil JT; Luchko T; Ludueña RF; Tuszynski JA
J Chem Inf Model; 2009 Feb; 49(2):424-36. PubMed ID: 19434843
[TBL] [Abstract][Full Text] [Related]
19. Computational design and biological testing of highly cytotoxic colchicine ring A modifications.
Torin Huzil J; Winter P; Johnson L; Weis AL; Bakos T; Banerjee A; Luduena RF; Damaraju S; Tuszynski JA
Chem Biol Drug Des; 2010 Jun; 75(6):541-50. PubMed ID: 20408852
[TBL] [Abstract][Full Text] [Related]
20. Novel Colchicine Derivatives and their Anti-cancer Activity.
Johnson L; Goping IS; Rieger A; Mane JY; Huzil T; Banerjee A; Luduena R; Hassani B; Winter P; Tuszynski JA
Curr Top Med Chem; 2017; 17(22):2538-2558. PubMed ID: 28056740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
